An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy.

Andre KonskiMytheryi BhargavanJean OwenRitsuko KomakiCorey J LangerElizabeth GoreRebecca PaulusHak ChoyDeborah-Watkins BrunerWalter J Curran

Published in: Journal of radiation oncology (2018)

In patients with Medicare insurance and with significant toxicity burden, RT on day 50 is the least expensive but also least effective treatment in this subset of patients treated on RTOG 94-10.

Keyphrases

locally advanced
radiation therapy
rectal cancer
palliative care
affordable care act
oxidative stress
squamous cell carcinoma
health insurance
healthcare
long term care
life cycle